InvestorsHub Logo
Followers 58
Posts 10034
Boards Moderated 1
Alias Born 09/21/2016

Re: Hosai post# 455970

Saturday, 04/06/2024 9:44:51 AM

Saturday, April 06, 2024 9:44:51 AM

Post# of 458275


It's funny that for all the Anavex bashers whenever you ask them what drugs should an Alzheimers patient take instead they never have an answer. The FDA don't have the luxury of going quiet on this point, they actually have to find the best drug for patients even if it's not perfect because no drug nor drug trial is

Hosai

Excellent points , thanks. IMO, the people and organizations each struggle to balance the risks of a massive win (w/ a few *****) vs a clear -well defined solution. IMO, Dr.M. and all the brilliant folks at AVXL are walking the tight rope over the fire pit of some qualified unknowns. These unknowns are more vapor than science but when people like Timo begin peeling possible onions of possible failure types , Dr.M. listens. There will ALWAYS BE UNKNOWN-UNKNOWNS...DEAL W/IT.

Reality needs to set in here as the scientific learning-proof process has exhausted itself for now. The truth is, "There are any number of "Unknown-Unknowns" , and leaders (like Dr.M.) just have to "suck it up and deal w/it it". The CNS science "Unknown-Unknowns " will reveal over time. AVXL science is the best shot science has and it needs to be acted on. If GAPS in science develop then, we deal with them as appropriate .

Not acting now w/the AVXL models we have presents greater risks to WW CNS patients than continuing to delay and second guess. This is a judgement-management (including WW regulatory bodies as appropriate) call that MUST BE MADE RIGHT AWAY. We are letting the UNKNOWNS control-delay the learning process.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News